ACIR
@acir_org
Accelerating Cancer Immunotherapy Research. A free weekly digest of the latest findings in the field. We also make cool images :) Listen to @ImmunoTalks.
ID: 875012589985640450
http://ACIR.org 14-06-2017 15:30:33
4,4K Tweet
2,2K Takipçi
1,1K Takip Edilen
To improve agonist CD40 Abs for clinical use, Osorio, Knorr, Weitzenfeld, et al. evaluated 2141-V11, an Fc-engineered anti-CD40 (with optimized FcγRIIB binding) in a phase 1 study (12 patients). bit.ly/4cJhCcg Rockefeller University
